WASHINGTON (dpa-AFX) - Alkermes plc (ALKS), a global biopharmaceutical company developing medicines in the fields of neuroscience and oncology, said nemvaleukin alfa, its investigational engineered
DUBLIN, March 11, 2021 /PRNewswire/ Alkermes plc (Nasdaq: ALKS) today announced that nemvaleukin alfa ("nemvaleukin", formerly referred to as ALKS 4230), the company's investigational engineered